This week, these five stocks have the worst ratings in Sales Growth, one of the eight Fundamental Categories on Portfolio Grader.

RNA also gets F’s in Earnings Momentum and Equity. Shares of the stock have declined 0.5% since January 1. This is worse than the Nasdaq, which has remained flat. For more information, get Portfolio Grader’s complete analysis of RNA stock.

Imperial Holdings, Inc. (IFT) is a specialty finance company with a focus on providing financing for individual life insurance policies and purchasing structured settlements. IFT gets F’s in Earnings Growth, Earnings Momentum, Analyst Earnings Revisions and Operating Margin Growth as well. Since January 1, IFT has fallen 4.8%. The stock currently has a trailing PE Ratio of 85.70. For more information, get Portfolio Grader’s complete analysis of IFT stock.

CBMG gets F’s in Earnings Momentum and Equity as well. For more information, get Portfolio Grader’s complete analysis of CBMG stock.

Chemocentryx, Inc. (CCXI) a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. CCXI also gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of CCXI stock.

Exact Sciences Corporation (EXAS) is a molecular diagnostics company, focuses on developing a molecular diagnostic technology for the early detection and prevention of colorectal pre-cancer and cancer. EXAS also gets an F in Equity. For more information, get Portfolio Grader’s complete analysis of EXAS stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.